As expected, IFN-γ significantly increased the migratory and invasive capabilities of SACC-83, and the similar effects have been documented in pancreatic cancer, gastric cancer, and melanoma.36–38 We then compared the responses of SACC-83 with SACC-LM upon IFN-γ treatment, and found SACC-LM exhibited a greater insensitivity in IFN-γ/STAT1/PD-L1 pathway activation, proliferation inhibition, and apoptosis induction. The gene discussed is STAT1; the disease is gastric cancer.